These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9718229)

  • 1. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
    Kaufer D
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():8-14. PubMed ID: 9718229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
    Cummings JL; Nadel A; Masterman D; Cyrus PA
    J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
    Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
    J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating response to metrifonate.
    Tariot PN
    J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
    Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
    Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Farlow MR; Cyrus PA
    Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
    McKeith IG
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
    Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
    Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
    Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
    J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metrifonate: a new agent for the treatment of Alzheimer's disease.
    Williams BR
    Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacology of metrifonate.
    Jann MW
    Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
    Knopman DS
    Neurology; 1998 May; 50(5):1203-5. PubMed ID: 9595961
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.
    Liu L; Ikonen S; Heikkinen T; Tapiola T; van Groen T; Tanila H
    Exp Neurol; 2002 Feb; 173(2):196-204. PubMed ID: 11822883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
    Sandson TA
    Neurology; 1999 Feb; 52(3):675-6. PubMed ID: 10025821
    [No Abstract]   [Full Text] [Related]  

  • 19. Metrifonate: update on a new antidementia agent.
    Ringman JM; Cummings JL
    J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
    Wynn ZJ; Cummings JL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):100-8. PubMed ID: 14564129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.